Effect of benralizumab treatment on the airway microbiome in COPD
In this study, the airway microbiome measured in sputum was unaffected by a targeted reduction of eosinophilic inflammation with benralizumab treatment.
Authors
- Michael R. Barer (ORCID: https://orcid.org/0000-0002-0377-3100)
- Corinne Hamblet (ORCID: https://orcid.org/0000-0001-5614-7261)
- Vijay Mistry (ORCID: https://orcid.org/0000-0002-3761-4714)
- Christopher Edward Brightling (ORCID: https://orcid.org/0000-0002-9345-4903)
- Mathew Richardson
- Maria Jison
- Christopher McCrae (ORCID: https://orcid.org/0000-0001-7184-9069)
- Koirobi Haldar
Institutions
- University of Leicester (GB)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- NIHR Leicester Biomedical Research Centre (GB)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1183/23120541.00802-2024
- Citations
- 2
- Primary Topic
- Pediatric health and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.49
Funders
- AstraZeneca